







# openhart Improvements of predictive power of B-type natriuretic peptide on admission by mathematically estimating its discharge levels in hospitalised patients with acute heart failure

Eiji Anegawa <sup>1</sup>, Hiroyuki Takahama <sup>1</sup>, Kunihiro Nishimura,<sup>2</sup> Daisuke Onozuka <sup>2</sup>, Yuki Irie,<sup>1</sup> Kenji Moriuchi,<sup>1</sup> Masashi Amano,<sup>1</sup> Atsushi Okada <sup>1</sup>, Makoto Amaki,<sup>1</sup> Hideaki Kanzaki,<sup>1</sup> Teruo Noguchi <sup>1</sup>, Kengo Kusano <sup>1</sup>, Satoshi Yasuda,<sup>1</sup> Chisato Izumi<sup>1</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/openhrt-2021-001603>).

**To cite:** Anegawa E, Takahama H, Nishimura K, *et al*. Improvements of predictive power of B-type natriuretic peptide on admission by mathematically estimating its discharge levels in hospitalised patients with acute heart failure. *Open Heart* 2021;**8**:e001603. doi:10.1136/openhrt-2021-001603

Received 25 January 2021  
Revised 9 March 2021  
Accepted 6 April 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

<sup>1</sup>Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan

<sup>2</sup>Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center, Suita, Japan

**Correspondence to**  
Dr Hiroyuki Takahama;  
takahama@cardio.med.tohoku.ac.jp

## ABSTRACT

**Backgrounds** Earlier studies showed that in patients with heart failure (HF), circulating levels of B-type natriuretic peptide (BNP) at hospital discharge (BNP<sub>dis</sub>) are more predictive of prognosis than BNP levels on admission (BNP<sub>ad</sub>). However, the mechanism underlying that difference has not been fully elucidated. We examined the association between confounding factors during hospitalisation and BNP<sub>dis</sub> in patients with HF.

**Methods** We identified patients admitted to our hospital for HF (BNP<sub>ad</sub> ≥ 100 pg/mL). Estimated left ventricular end-diastolic pressure (eLVEDP) was calculated using echocardiographic data. To identify the factors associated with the relation between BNP<sub>ad</sub> and BNP<sub>dis</sub>, we performed a stepwise regression analysis of retrospective data. To validate that analysis, we performed a prospective study.

**Results** Through stepwise regression of the patient data (n=688, New York Heart Association 3–4, 88%), we found age, blood urea nitrogen and eLVEDP to be significantly (p<0.05) associated with BNP<sub>dis</sub>. Through multivariate analysis after accounting for these factors, we created a formula for predicting BNP levels at discharge (*predicted*-BNP<sub>dis</sub>) from BNP<sub>ad</sub> and other parameters measured at admission (p<0.05). By statistically adjusting for these factors, the prognostic power of BNP<sub>ad</sub> was significantly improved (p<0.001). The prospective study also confirmed the strong correlation between *predicted*-BNP<sub>dis</sub> and BNP<sub>dis</sub> (n=104, r=0.625, p<0.05).

**Conclusion** This study showed that statistically accounting for confounding factors affecting BNP levels improves the predictive power of BNP levels measured at the time of hospital admission, suggesting that these confounding factors are associated with lowering predictive power of BNP on admission.

**Trial registration number** UMIN 000034409, 00035428.

## INTRODUCTION

B-type natriuretic peptide (BNP) is widely used as a predictive biomarker in patients

## Key questions

### What is already known about this subject?

► Predictive power of B-type natriuretic peptide (BNP) levels at hospital admission (BNP<sub>ad</sub>) is inferior to that of BNP levels at discharge (BNP<sub>dis</sub>) in patients with acute heart failure (HF). However, the mechanism underlying these differences has not been fully elucidated.

### What does this study add?

► Through multivariate analysis after accounting for known confounding factors related to circulating BNP levels, we created a formula for predicting BNP levels at discharge (*predicted*-BNP<sub>dis</sub>) from BNP<sub>ad</sub> and other parameters measured at admission.  
► This study showed that statistically accounting for confounding factors affecting BNP levels improves the predictive power of BNP levels measured at the time of hospital admission.

### How might this impact on clinical practice?

► This *predicted*-BNP<sub>dis</sub> has superior predictive power for clinical outcomes to BNP<sub>ad</sub>. This may contribute to the risk stratification of acute HF and primary intensive care management in acute vulnerable phases of HF.

with heart failure (HF).<sup>1</sup> However, earlier studies showed that in patients with acute HF, the predictiveness of BNP levels measured at hospital admission (BNP<sub>ad</sub>) for clinical outcomes is inferior to BNP levels measured at discharge (BNP<sub>dis</sub>).<sup>2,3</sup> Although the reason for the insufficient predictive power of BNP<sub>ad</sub> compared with BNP<sub>dis</sub> in these patients has not been fully elucidated, several confounding factors are well known to influence circulating BNP levels (eg, left ventricular end-diastolic pressure (LVEDP)

and renal function).<sup>4-7</sup> However, how these parameters influence the lower predictability of  $\text{BNP}_{\text{ad}}$  than that of  $\text{BNP}_{\text{dis}}$  remains uncertain.

Given the importance of clinical risk stratification for hospitalised patients with heterogeneous clinical syndromes, this study aimed to identify the confounding factors affecting  $\text{BNP}_{\text{ad}}$  that are associated with  $\text{BNP}_{\text{dis}}$ . We also tested the hypothesis: whether statistical adjustments of these confounding factors are related to predictive power of  $\text{BNP}_{\text{ad}}$  improvements in patients with acute HF.

## METHODS

### Study design

This was a cross-sectional study of patients with HF admitted to the National Cerebral and Cardiovascular Center of Japan.

### Study population

#### Retrospective study

Included in the retrospective study were 688 patients hospitalised for HF between January 2013 and March 2016 ( $\text{BNP}$  on admission:  $\geq 100$  pg/mL). We excluded patients who did not undergo a blood test and echocardiography, who underwent implantation of a left ventricular (LV) assist device ( $n=3$ ), or who died in the hospital ( $n=24$ ) during the corresponding hospitalisation. We also excluded patients who underwent mitral valve surgery ( $n=85$ ) due to its influence on transmitral flow and septal mitral annular velocity.

Diagnosis of HF was based on the Framingham criteria.<sup>8</sup> Whether or not a HF episode met the Framingham criteria was determined by each attending physician and an investigator (H Takahama) via medical record review. We excluded patients who did not meet the criteria, as judged by the investigator and the attending physician for each patient. According to the guidelines of the Japanese Circulation Society,<sup>9</sup> we defined the cut-off value of plasma BNP level for diagnosis of HF as 100 pg/mL.

#### Prospective study

We prospectively collected data from 104 patients between January and June in 2019 based on the same criteria used for the retrospective study.

### Echocardiography

Through medical chart review, we retrospectively reviewed the echocardiography data collected during the hospitalisation. LV dimensions were measured according to the American Society of Echocardiography guidelines.<sup>10</sup> LV ejection fraction (EF) was measured using the modified Simpson method or the semiquantitative two-dimensional visual estimate method, as described previously.<sup>11</sup> Transmitral inflow was measured with pulsed-wave Doppler using standard methods as described previously.<sup>12</sup> The septal mitral annular early diastolic velocity ( $e'$ ) was determined with spectral tissue Doppler imaging. LVEDP was calculated as  $11.96 + 0.596 \times \text{early diastolic transmitral flow velocity (E)}/e'$ , as previously reported.<sup>13</sup>

### Measurement of plasma BNP concentration

All biochemical analyses were performed as routine clinical examinations. BNP were measured by human brain natriuretic peptide kit (TOSOH corporation, Tokyo, Japan).

### Clinical outcomes

After the admission date, we investigated through medical chart review or a letter all causes of death and rehospitalisation for HF. Combined clinical events were defined as all-cause death or rehospitalisation for HF.

### Ethics

The study was designed to be carried out without obtaining individual informed consent according to the 'opt-out' principle. Instead, we publicised a summary of the study protocol with the contact information for our office on the institution website, which provided patients with the ability to refuse enrolment to the study. This study protocol was also registered in the Japanese University Hospital Medical Information Network Clinical Trials Registration.

### Statistical analyses

Results are expressed as the median and IQR. Fisher's exact test or the  $\chi^2$  test was used to compare categorical variables, as appropriate. With regard to baseline patient characteristics, Wilcoxon's rank-sum test was used for comparison of continuous variables between two groups. HRs with 95% CIs and probability ( $p$ ) values determined using the likelihood ratio test are presented. The area under the receiver operating characteristics (ROC) curve (AUC) and C-statistics were also calculated. AUCs were compared using an algorithm developed by DeLong *et al.*<sup>14</sup> Pairwise comparisons of the areas under multiple ROC curves were made using the `roccomp` command in Stata. Multivariate analysis/regression was used to test multiple covariates. All tests were two tailed, and values of  $p < 0.05$  were considered significant. All statistical analyses were performed using JMP V.9 statistical analysis software (SAS Institute Japan, Inc, Tokyo, Japan) and Stata V.15 (Stata Corporation LLC, College Station, Texas, USA).

## RESULTS

### Retrospective data analysis

Using the inclusion and exclusion criteria described in the Methods section, we identified 688 patients with HF from our database. The patient characteristics on admission were as follows (table 1): New York Heart Association class III and IV on admission, 43% and 45%, respectively; median LVEF: 35% (IQR: 24%–55%); median LV end-diastolic diameter (LVEDD), 56 mm (IQR: 48–64 mm); and median plasma BNP levels, 671 pg/mL (IQR: 370–1170 pg/mL). Median hospitalisation length was 19.5 days (IQR: 14–27 days). The patients treated without beta-blockers were often observed in those with valvular regurgitation and with HF with preserved EF. Based on earlier studies, we selected the following clinical

**Table 1** Baseline patient characteristics

	Overall patients
Patients number	688
Age (years)	78 (69–84)
Gender (male)	429 (62)
BMI (kg/m <sup>2</sup> )	22.5 (20.2–25.4)
<b>NYHA class</b>	
Class III	296 (43)
Class IV	311 (45)
<b>Aetiology</b>	
Ischaemic	232 (34)
Non-ischaemic	172 (25)
Valvular	98 (14)
Hypertensive	149 (22)
Others	37 (5)
<b>History</b>	
Hypertension	490 (71)
Atrial fibrillation	345 (50)
Diabetes mellitus	250 (36)
<b>Vital signs and others on admission</b>	
Systolic blood pressure (mm Hg)	120 (105–138)
Diastolic blood pressure (mm Hg)	68 (58–81)
Heart rate (bpm)	77 (66–92)
<b>Echocardiography</b>	
LVEDD (mm)	56 (48–64)
LVESD (mm)	44 (34–54)
LVEF (%)	35 (24–55)
E/e'	14.4 (10.6–19.4)
eLVEDP (mm Hg)	20.5 (18.3–23.5)
<b>Laboratory data</b>	
BNP <sub>ad</sub> (pg/mL)	671 (370–1170)
BNP <sub>dis</sub> (pg/mL)	280 (153–468)
eGFR (mL/min/1.73 m <sup>2</sup> )	46 (30–60)
BUN (mg/dL)	24 (18–34)
Hb (g/dL)	12.2 (10.7–13.4)
Hct (%)	37 (33–41)
CRP (mg/dL)	0.35 (0.12–1.20)
WCC (×10 <sup>3</sup> /uL)	6.4 (5.1–8.0)
T-Cho (mg/dL)	154 (130–178)
HDL-C (mg/dL)	42 (34–51)
LDL-C (mg/dL)	88 (70–110)
<b>Medications</b>	
<b>On admission</b>	
ACEi or ARB	283 (41)
Beta-blockers	401 (58)
Aldosterone antagonists	186 (27)
Loop diuretics	418 (61)

Continued

**Table 1** Continued

	Overall patients
Dobtamin	68 (10)
<b>At discharge</b>	
ACEi or ARB	516 (75)
Beta-blockers	539 (78)
Aldosterone antagonists	297 (43)
Loop diuretics	585 (85)
Median observation period (days)	623 (188–730)

Values are the median (IQR) and patients number, n (%).

ACEi, ACE inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP<sub>ad</sub>, circulating B-type natriuretic peptide levels on admission; BNP<sub>dis</sub>, circulating B-type natriuretic peptide levels at hospital discharge; BUN, blood urea nitrogen; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; eLVEDP, estimated left ventricular end-diastolic pressure; Hb, haemoglobin; Hct, haematocrit; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; NYHA, New York Heart Association; T-cho, total cholesterol; WCC, white cell count.

parameters known to influence circulating BNP levels for analysis: age, sex,<sup>4</sup> LVEDP,<sup>5 15</sup> blood pressure,<sup>16</sup> heart rate,<sup>7</sup> body mass index (BMI),<sup>6</sup> LVEF,<sup>17 18</sup> end-diastolic volume,<sup>17</sup> LVEDD,<sup>18</sup> cholesterol levels,<sup>19</sup> anaemia,<sup>20</sup> renal function,<sup>7 20</sup> atrial fibrillation<sup>21</sup> and diabetes mellitus.<sup>22</sup>

The results of univariate analyses of the association between BNP<sub>dis</sub> and the selected parameters are shown in table 2. Age, BMI, systolic blood pressure, diastolic blood pressure, LVEDD, LVEF, estimated LVEDP (eLVEDP), estimated glomerular filtration, blood urea nitrogen (BUN), haemoglobin, hematocrit, total cholesterol and low-density lipoprotein cholesterol on admission were all associated with BNP<sub>dis</sub> after adjusting for BNP<sub>ad</sub>. Stepwise analysis identified the following parameters as significantly associated with BNP<sub>dis</sub> after accounting for BNP<sub>ad</sub> levels: age, systolic blood pressure, LVEF, eLVEDP and BUN levels (table 3). Subsequent multivariate analysis revealed the parameter estimates of the above factors to be: 3.81 (age), -1.09 (systolic blood pressure), -0.87 (LVEF), 6.72 (eLVEDP), 3.48 (BUN) and 0.21 (BNP<sub>ad</sub>). Using those data, we developed the following formula to predict BNP<sub>dis</sub> from BNP<sub>ad</sub>: the 'predicted-BNP<sub>dis</sub>' = 3.81 × age - 1.09 × systolic blood pressure - 0.87 × LVEF + 6.72 × eLVEDP + 3.48 × BUN + 0.21 × BNP<sub>ad</sub> - 184.5. Next, the analysis of association non-pharmacological intervention on the relation between the parameters used for estimation of the predicted-BNP<sub>dis</sub> and BNP<sub>dis</sub> were performed because the therapeutic intervention might influence the discharge levels of BNP. As shown in online supplemental table 1, no statistical significance was found. In addition, there was significant differences in both BNP<sub>ad</sub> and BNP<sub>dis</sub> in patients with initial admission and rehospitalisation for HF. As shown in online supplemental table 2, both BNP levels were higher in patients with readmission than



**Table 2** Association of discharge levels of BNP with clinical parameters on admission (univariate analysis)

Variables	r	P value
Age	0.1550	<0.0001
Gender	n/a	0.3940
BMI (kg/m <sup>2</sup> )	-0.2167	<0.0001
Atrial fibrillation	n/a	0.1084
Diabetes mellitus	n/a	0.9110
Systolic blood pressure (mm Hg)	-0.1109	0.0036
Diastolic blood pressure (mm Hg)	-0.0875	0.0220
Heart rate (bpm)	-0.0657	0.0854
LVEDD (mm)	0.1084	0.0045
LVEF (%)	-0.1822	<0.0001
eLVEDP (mm Hg)	0.1460	0.0001
BNP <sub>ad</sub> (pg/mL)	0.5779	<0.0001
eGFR (mL/min/1.73 m <sup>2</sup> )	-0.3153	<0.0001
BUN (mg/dL)	0.3438	<0.0001
Hb (g/dL)	-0.1635	<0.0001
Hct (%)	-0.1529	<0.0001
T-Cho (mg/dL)	-0.1312	0.0006
HDL-C (mg/dL)	-0.0362	0.3476
LDL-C (mg/dL)	-0.0793	0.0388

Abbreviations are shown in [table 1](#).


those in initial admission. The correlation of the *predicted*-BNP<sub>dis</sub> with BNP<sub>dis</sub> was similar between the patients with initial admission and readmission ( $p < 0.05$ ).

During the follow-up period (median: 623 days, IQR: 188–730 days), combined clinical events occurred in

**Table 3** Stepwise regression analysis for association of BNP<sub>dis</sub> with variables on admission

Variables	P value
Age	0.0004
BMI (kg/m <sup>2</sup> )	0.7260
Systolic blood pressure (mm Hg)	0.0074
Diastolic blood pressure (mm Hg)	0.4822
LVEDD (mm)	0.1740
LVEF (%)	0.0157
eLVEDP (mm Hg)	0.0066
eGFR (mL/min/1.73 m <sup>2</sup> )	0.6155
BUN (mg/dL)	<0.0001
Hb (g/dL)	0.0656
Hct (%)	0.4669
T-Cho (mg/dL)	0.6299
LDL-C (mg/dL)	0.7344

Stepwise regression analysis for association of BNP<sub>dis</sub> with variables on admission after accounting for BNP<sub>ad</sub>. Abbreviations are shown in [table 1](#).



**Figure 1** Association between BNP levels at hospital discharge and levels on admission or predicted BNP levels at discharge (*predicted*-BNP<sub>dis</sub>) and their prognostic power. (A) Correlation between circulating BNP levels at hospital discharge (BNP<sub>dis</sub>) and BNP on admission (BNP<sub>ad</sub>). (B) Correlation between BNP<sub>dis</sub> and predicted BNP levels at discharge (*predicted*-BNP<sub>dis</sub>). (C) Area under the receiver operating characteristics curve (AUC) analysis of the occurrence of the combined clinical events. AUC for the predicted BNP levels at discharge (*predicted*-BNP<sub>dis</sub>; blue) was superior to BNP levels on admission (BNP<sub>ad</sub>; red) ( $p < 0.001$ ). (D) There was no significant difference in the AUC for the *predicted*-BNP<sub>dis</sub> (blue) and BNP levels at discharge (BNP<sub>dis</sub>; red). BNP<sub>ad</sub>, B-type natriuretic peptide on hospital admission; BNP<sub>dis</sub>, B-type natriuretic peptide at discharge.


295 (43%) patients: all causes of death ( $n = 68$ , 10%) and rehospitalisation for HF ( $n = 227$ , 33%). [Figure 1](#) shows the correlation between BNP<sub>dis</sub> and BNP<sub>ad</sub> ([figure 1A](#)) and between BNP<sub>dis</sub> and *predicted*-BNP<sub>dis</sub> ([figure 1B](#)). However, AUC analysis showed that *predicted*-BNP<sub>dis</sub> was significantly more predictive of outcome than BNP<sub>ad</sub> ( $p < 0.001$ ) and was comparable with the predictiveness of BNP<sub>dis</sub> ([figure 1C,D](#)).

### Prospective data analysis

The prospective study revealed similar relationships between BNP<sub>ad</sub> or *predicted*-BNP<sub>dis</sub> and BNP<sub>dis</sub> ([figure 2A,B](#)).

### DISCUSSION

Circulating BNP levels are affected by a number of confounding factors during the acute phase of HF and are associated with fluctuations in measured BNP levels during the initial few days after hospital admission or intensive treatments.<sup>23 24</sup> These fluctuations are mainly due to changes in ventricular preload and the systemic fluid overload state. Our retrospective study confirmed known confounding factors affecting BNP levels and showed that these factors statistically were associated with



**Figure 2** Association between BNP levels at hospital discharge and levels on admission or predicted BNP levels at discharge (*predicted*-BNP<sub>dis</sub>) in a prospective study. (A) Correlation between circulating BNP levels at hospital discharge (BNP<sub>dis</sub>) and BNP levels on admission (BNP<sub>ad</sub>). (B) Correlation between BNP<sub>dis</sub> and predicted BNP levels at discharge (*predicted*-BNP<sub>dis</sub>). Note the similarity between the results of the prospective and retrospective studies. BNP<sub>ad</sub>, B-type natriuretic peptide on hospital admission; BNP<sub>dis</sub>, B-type natriuretic peptide at discharge.

lowering the predictive power of BNP<sub>ad</sub> levels for patient outcomes. This study also showed that after statistically accounting for these confounding factors, the predictive power of the resultant BNP value (*predicted*-BNP<sub>dis</sub>) did not significantly differ from that of BNP<sub>dis</sub>. Moreover, the finding of the correlation of *predicted*-BNP<sub>dis</sub> with BNP<sub>dis</sub> was validated by obtaining similar results in a prospective study.

Several earlier studies reported on the factors influencing circulating BNP levels. For example, Iwanaga *et al*<sup>5</sup> measured LVEDP using a LV catheter system and clearly demonstrated that LV wall stress strongly correlated with plasma BNP levels. In addition, factors such as increased cardiac preload likely due to excess body fluid, which may stretch ventricular cardiomyocytes, sharply increases circulating BNP levels in patients with HF. By the time BNP<sub>dis</sub> levels are measured, however, the patient has reached an appropriate volume state through removal of the excess body fluid. Consequently, BNP<sub>dis</sub> levels may more closely reflect myocardial quality per se or a ‘true ventricular trait’. This may explain why BNP<sub>ad</sub> levels measured during the acute phase of HF have less predictive power than BNP<sub>dis</sub> levels. In the present study, we observed that after accounting for several factors, including LVEDP and LVEF, as well as blood pressure and renal function, the predicted BNP levels, which we termed *predicted*-BNP<sub>dis</sub>, strongly correlated with BNP<sub>dis</sub> levels and were equally predictive of patient outcome.

Thus, by determining the impact of factors responsible for the difference in predictive power between BNP<sub>ad</sub> and BNP<sub>dis</sub>, we were able to shed light on the relationship between these factors and BNP<sub>dis</sub>. These findings may further our understanding of BNP levels, which are influenced by various factors in patients with acute HF.

### Limitation

The present study has several limitations. First, this was a single-centre investigation with a limited number of patients. Nevertheless, we were able to confirm a formula

that predicts BNP levels at discharge from clinical parameters at the time of admission. Second, several patients did not undergo a blood test for BNP and E/e’; we excluded these patients from our analysis. Next, it is widely known that the therapeutic intervention might influence the discharge levels of BNP. These therapeutic interventions might also influence the relationship between the clinical parameters on admission with the BNP<sub>dis</sub>, although no statistical association were found in online supplemental table 1. Furthermore, this study enrolled the patients between 2013 and 2016, and at that time, sacubtrilvalsartan was not approved in Japan, which is known to influence circulating BNP levels. Further investigation will be necessary to confirm the effects of sacubtrilvalsartan on the predicted BNP levels at discharge. The association of the *predicted*-BNP<sub>dis</sub> with BNP<sub>dis</sub> is statistically significant, but the degree of correlation was modest; we could not exclude the possibility that the other unknown factor or therapeutic effects, which are not included for the estimation of BNP<sub>dis</sub> in this study, might be also associated with the regulation of BNP. Taken together, this study was not designed to investigate the effects of the prospectively controlled pharmacological or non-pharmacological intervention on BNP<sub>dis</sub>. Further prospective study will be necessary to address these problems.

In addition, there was no discharge criteria for the research in this study, and in general, discharges were determined by the attending physician. Although the discharge levels are determined by clinical findings including BNP levels in stable phases of HF, the variation of HF severity at discharge exists among the attending physicians, which might create the further variation of the discharge levels of BNP.

### CONCLUSION

We have shown the confounding factors affecting measured BNP levels and demonstrated BNP prediction at discharge in hospitalised patients with HF. This predicted BNP values have superior predictive power for clinical outcomes to raw BNP values on admission. This may contribute to the risk stratification of acute HF and primary intensive care management in acute vulnerable phases of HF.

**Acknowledgements** The authors would like to thank the research coordinator and assistants in our institute for the data collection.

**Contributors** HT, EA, TN, KK, SY and CI contribute to design of the work; HT, EA, DO, KN contribute to the acquisition and analysis of data for the work; HT, EA, HK, SY, YI, AO, MA, MA, KM and CI contributed to drafting the work or revising it critically for important intellectual content; final approval was done by HT.

**Funding** This work was supported by the Intramural Research Fund of the National Cerebral and Cardiovascular Centre of Japan (grants 30-1-3 to CI).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** The study protocol was approved by the institutional review board of the National Cerebral and Cardiovascular Centre (M26-127 and M30-155).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** No data are available.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

#### ORCID iDs

Eiji Anegawa <http://orcid.org/0000-0003-1534-4431>  
 Hiroyuki Takahama <http://orcid.org/0000-0003-4155-1936>  
 Daisuke Onozuka <http://orcid.org/0000-0001-9596-9188>  
 Atsushi Okada <http://orcid.org/0000-0002-0087-4168>  
 Teruo Noguchi <http://orcid.org/0000-0001-5372-4932>  
 Kengo Kusano <http://orcid.org/0000-0002-5760-9285>

#### REFERENCES

- 1 Chow SL, Maisel AS, Anand I, *et al*. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American heart association. *Circulation* 2017;135:e1054–91.
- 2 Hamatani Y, Nagai T, Shiraishi Y, *et al*. Long-Term prognostic significance of plasma B-type natriuretic peptide level in patients with acute heart failure with reduced, Mid-Range, and preserved ejection fractions. *Am J Cardiol* 2018;121:731–8.
- 3 Bettencourt P, Azevedo A, Pimenta J, *et al*. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. *Circulation* 2004;110:2168–74.
- 4 Redfield MM, Rodeheffer RJ, Jacobsen SJ, *et al*. Plasma brain natriuretic peptide concentration: impact of age and gender. *J Am Coll Cardiol* 2002;40:976–82.
- 5 Iwanaga Y, Nishi I, Furuichi S, *et al*. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. *J Am Coll Cardiol* 2006;47:742–8.
- 6 Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. *J Am Coll Cardiol* 2006;47:85–90.
- 7 Tsutamoto T, Wada A, Sakai H, *et al*. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. *J Am Coll Cardiol* 2006;47:582–6.
- 8 Ho KK, Anderson KM, Kannel WB, *et al*. Survival after the onset of congestive heart failure in Framingham heart study subjects. *Circulation* 1993;88:107–15.
- 9 Tsutsui H, Isobe M, Ito H, *et al*. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart Failure — digest version. *Circ J* 2019;83:2084–184.
- 10 Lang RM, Bierig M, Devereux RB, *et al*. Recommendations for chamber quantification: a report from the American Society of echocardiography's guidelines and standards Committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European Society of cardiology. *J Am Soc Echocardiogr* 2005;18:1440–63.
- 11 Imazu M, Takahama H, Asanuma H, *et al*. Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease. *Am J Physiol Heart Circ Physiol* 2014;307:H1504–11.
- 12 Patel JB, Borgeson DD, Barnes ME, *et al*. Mitral regurgitation in patients with advanced systolic heart failure. *J Card Fail* 2004;10:285–91.
- 13 Lam CSP, Roger VL, Rodeheffer RJ, *et al*. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. *Circulation* 2007;115:1982–90.
- 14 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 1988;44:837–45.
- 15 Maeda K, Tsutamoto T, Wada A, *et al*. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. *Am Heart J* 1998;135:825–32.
- 16 Kario K, Nishikimi T, Yoshihara F, *et al*. Plasma levels of natriuretic peptides and adrenomedullin in elderly hypertensive patients: relationships to 24 H blood pressure. *J Hypertens* 1998;16:1253–9.
- 17 Yan RT, White M, Yan AT, *et al*. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. *Am J Cardiol* 2005;96:698–704.
- 18 Masson S, Latini R, Anand IS, *et al*. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (Val-HeFT) data. *Clin Chem* 2006;52:1528–38.
- 19 Takeuchi H, Sata M. The relationship among brain natriuretic peptide (BNP), cholesterol and lipoprotein. *Heart Asia* 2012;4:11–15.
- 20 Hogenhuis J, Voors AA, Jaarsma T, *et al*. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. *Eur J Heart Fail* 2007;9:787–94.
- 21 Knudsen CW, Omland T, Clopton P, *et al*. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. *J Am Coll Cardiol* 2005;46:838–44.
- 22 Gruden G, Landi A, Bruno G. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. *Diabetes Care* 2014;37:2899–908.
- 23 Takahama H, Takashio S, Nishikimi T, *et al*. Ratio of pro-B-type natriuretic peptide (BNP) to total BNP is decreased in mild, but not severe, acute decompensated heart failure patients: a novel compensatory mechanism for acute heart failure. *Int J Cardiol* 2018;258:165–71.
- 24 Ito K, Kawai M, Nakane T, *et al*. Serial measurements associated with an amelioration of acute heart failure: an analysis of repeated quantification of plasma BNP levels. *Eur Heart J Acute Cardiovasc Care* 2012;1:240–7.